NCT05484011 - A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

March 4, 2024

Study Completion Date

March 4, 2024

Conditions

Metastatic Pancreatic Adenocarcinoma

Interventions

BIOLOGICAL

odetiglucan

Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Odetiglucan acts as a Pathogen-Associated Molecular Pattern (PAMP).

BIOLOGICAL

CDX-1140

A fully human agonist anti-CD40 monoclonal antibody

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania, Abramson Cancer Center, Philadelphia

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

85258

HonorHealth Research Institute, Scottsdale